以下是ASCO2014IL-2治療惡性腫瘤的研究摘要的其中4篇的中文概述,涉及的惡性腫瘤有黑色素瘤、腎癌和成神經細胞瘤,治療方案有IL-2聯合化療、聯合靶向治療及聯合其他免疫療法。

 

 

() IL-2治療惡性腫瘤的中文概述

 

 

1. Citation: J Clin Oncol 32, 2014 (suppl; abstr e20008)

 

摘要鏈接:http://abstracts.asco.org/144/AbstView_144_126671.html

 

The experience of administration of high-dose recombinant interleukin-2 in combination with chemotherapy in the management of disseminated skin melanoma.

 

Abstract:

 

Background: Interleukin-2 (Biotech, Russia) is a complete structural and functional analogue of human endogenous interleukin-2 produced from nonpathogenic Saccharomyces cerevisiae. Our retrospective study evaluated the results of the first-line chemoimmunotherapy of 71 patients with disseminated skin melanoma treated with interleukin-2 from 2004 till 2012.

Methods: We retrospectively evaluated efficacy and safety of chemotherapy dacarbazine 800 mg/m2, d 1 and cisplatin 20 mg/m2, d 1–4 (control arm, n=31). In the treatment arm chemotherapy was supplement of one of the following immunotherapy regiments: high-dose IL-2 (9 mg/m2, d 1–5) or gradual dose reduction IL-2 (18 mg/m2, d 1; 9 mg/m2, d 2; 4 mg/m2, d 3–4) (n=71). The median follow –up was 10, 0 months.

Results: The objective response rate was 33.8 % and 19.4% in the treatment and control arms respectively. Four complete responses were registered in the treatment arm only (5.6%). The median PFS was 5.3 and 3.2 (p=0.04), the median overall survival was 12.4 and 8.4 months (p=0.1) among the patients treated with chemoimmunotherapy and with chemotherapy alone respectively. The blood serum level of lactate dehydrogenase (LDH) exceeding more than 1.5 fold the upper reference value was an unfavourable prognostic factor with no impact of the treatment type (chemotherapy or chemoimmunotherapy) on its efficacy. At the same time, chemoimmunotherapy for disseminated skin melanoma patients with the LDH level not exceeding more than 1.5-fold the upper reference value increased the median PFS up to 6.3 months and the median overall survival up to 14.7 months. All adverse effects were overcome with conventional medications and had not caused cancels of immunotherapy.

Conclusions: Our experience confirmed that immunochemotherapy with high-dose interleukin-2 is an effective treatment of disseminated skin melanoma, is satisfactily tolerated and may be beneficial in patients with the LDH level not exceeding more than 1.5-fold the upper reference value.

 

 

高劑量IL-2聯合化療治療散播性皮膚黑色素瘤

 

治療方案:2004年至2012年收治的71位散播性皮膚黑色素瘤患者行一線化學免疫療法。對照組31例,僅接受化療,第1天予達卡巴嗪800 mg/m2,第1-4天予順鉑20 mg/m2。治療組71例,在化療的同時接受IL-2治療,IL-2用藥方案二者擇其一:第1-5天予高劑量IL-2,每天9 mg/m2;或IL-2劑量遞減,第118 mg/m2,第29 mg/m2,第3-44 mg/m2。中位隨訪期是100個月。

結果:治療組和對照組的客觀緩解率分別是33.8%19.4%。僅治療組有完全緩解患者4(5.6%)。治療組和對照組的中位無進展生存期分別是5.33.2個月(p=0.04),中位總生存期分別是12.48.4個月(p=0.1)。對兩組患者來說,血清乳酸脫氫酶水平(LDH)超過其參考值上限的1.5倍是一個不利的預后因子。治療組患者中,LDH水平低于參考值上限1.5倍的患者,中位無進展生存期增加了6.3個月,中位總生存期增加了14.7個月。所有不良反應均予普通藥物處理即可,沒有患者因不良反應退出免疫治療。

結論:研究結果說明高劑量IL-2為主的化學免疫療法治療散播性皮膚黑色素瘤是有效的,安全可耐受的,且對LDH水平低于參考值上限1.5倍的患者可能更為有利。

 

 

2. Citation: J Clin Oncol 32:5s, 2014 (suppl; abstr 4523)

 

摘要鏈接:http://abstracts.asco.org/144/AbstView_144_129462.html

 

High-dose (HD) IL-2 for metastatic renal cell

carcinoma (mRCC) in the targeted therapy era: Extension of

OS benefits beyond complete response (CR) and partial response (PR).

 

Abstract:

 

Background: HD IL-2 has been reported to have a overall response rate (ORR) for mRCC of 15% and a median OS of 19 months (Fyfe,1995), however, the studies that led to its regulatory approval are >15 years old and were performed in an era preceding targeted therapies.

Methods: The PROCLAIM registry (www.proclaimregistry.com), a HD IL-2 observational database currently with over 30 participating sites, consists of a retrospective cohort (treated between 2007 and 2012) informing an ongoing prospective cohort (~ 600 patients). We report on the retrospective mRCC subjects (n=97, 13 sites) with survival status determined as of November 2013 and a median follow-up of 32 months. Sites were encouraged to enroll patients sequentially. Inclusion criteria required that patients have received at least one dose of HD IL-2.

Results: The ORR was 22% (8% CR and 14% PR). Of 97 subjects, 36 were confirmed deceased and 61 were known to be alive, none were lost to follow-up. The median OS was 51 months, compared to a median OS range of 5-35 months for FDA-approved targeted agents (Harrison, 2013). There was significant clinical benefit in patients with CR, PR, and stable disease (SD), none of which reached median OS compared to 37.9 months in patients with progressive disease (PD). There is a significant advantage in PROCLAIM for those patients treated 1st vs. 2ndline HD IL-2; the median OS was 61.8 months (n=82) vs 15.3 months (n=15), respectively. The clinical benefit of HD IL-2 therapy as front line is consistent with published data (Birkhauser, 2013). No deaths due to IL-2 related toxicity were reported in the retrospective cohort.

Conclusions: The PROCLAIM registry documents a vastly improved OS for HD IL-2 compared to historical results during a time interval marked by the advent of targeted therapy for advanced RCC. Response to IL-2 (CR or PR) is associated with prolonged survival, however, stable disease as well as front line use also appears to positively impact survival. Issues including patient selection characteristics and treatment sequencing are hypotheses currently being explored in the prospective database.

 

 

高劑量IL-2在靶向治療時代治療轉移性腎癌

 

治療方案:報道了97例轉移性腎癌患者截至201311月的生存狀況。中位隨訪期是32個月。每位患者至少接受過一次高劑量IL-2治療。

結果:總緩解率(ORR)22%(8% CR14% PR)97例患者中,36例確認死亡,61例確認存活,無一例失訪。中位總生存期(OS)51個月,而FDA批準的靶向藥物治療的中位OS5-35個月。對CRPRSD的患者明顯更有利,其OS均達到了中位OS,而PD患者的OS37.9個月。未發生因IL-2不良反應引起的死亡。

結論:IL-2治療中,CRPR患者的生存期更長,而本報道顯示IL-2治療也明顯有利于延長SD患者的生存期。

 

 

3. Citation: J Clin Oncol 32, 2014 (suppl; abstr e15550)

 

摘要鏈接:http://abstracts.asco.org/144/AbstView_144_127215.html

 

Prior high-dose IL-2 therapy (HDIL2) may

improve the outcome of sunitinib (Su) treatment (tx) in

patients (pts) with metastatic renal cell carcinoma (mRCC).

 

Abstract:

 

Background: Targeted txs are the tx of choice in most mRCC pts. However, HDIL2 which may produce durable responses in a small percentage of cases, is still an option in carefully selected pts. While the effect of prior HDIL2 on the outcome of targeted txs in mRCC pts is poorly defined, a recent single center report (Birkh?user FD, Cancer J 2013) revealed an improved disease-specific survival in pts treated with prior HDIL2. We aimed to study the effect of prior HDIL2 tx on outcome of mRCC pts treated with sunitinib.

Methods: Records from 302 mRCC pts treated with Su from 2004 to 2013 in 9 centers across 2 countries were retrospectively reviewed. We compared the response rate, progression free survival (PFS), and overall survival (OS), between post HDIL2 pts (n=27) and individually matched tx na?ve pts (n=27). Progression free survival and overall survival were determined by Cox regression.

Results: All pts had prior nephrectomy and clear cell histology. The groups were matched by age (median 61), gender (male 74%), Heng risk (favorable 37%, intermediate 59%, poor 4%), sunitinib induced hypertension (67%), sunitinib dose reduction/treatment interruption (41%), smoking status (active 7%), use of angiotensin system inhibitors (41%), the presence of more than one metastases site (96%), and pre-tx neutrophil to lymphocyte ratio (> 3 in 22%). Furthermore, they were balanced regarding the presence of lung (68%), liver (31%), and bone (43%) metastases, and the use of bisphosphonates (32%). In prior HDIL2 versus tx na?ve pts, objective response was partial response/stable disease 89% (n=24) versus 74% (n=20), and progressive disease at first imaging evaluation within the first 3 months (mos) 11% (n=3) versus 26% (n=7) (p=0.29, OR 2.4). Median progression free survival was 21 versus 12 mos (HR 2.3, p=0.005), and median overall survival 25 versus 20 mos (HR 2.2, p=0.013).

Conclusions: In metastatic renal cell carcinoma patients treated with sunitinib, prior high dose IL-2 therapy may improve the outcome.

 

 

舒尼替尼治療前應用大劑量IL-2可提高轉移性腎癌療效

 

治療方案:研究組27例,舒尼替尼治療前先應用高劑量IL-2治療,對照組27例,但用舒尼替尼治療。比較兩組的緩解率,無進展生存期(PFS)和總生存期(OS)

結果:研究組和對照組的客觀緩解率分別是89%(n=24)74%(n=20);根據第一次影像學評價,前3個月疾病進展的患者分別占11%(n=3)26%(n=7) (p=0.29, OR 2.4);中位無進展生存期分別是21個月和12個月(HR 2.3, p=0.005);中位總生存期分別是25個月和20個月(HR 2.2, p=0.013)

結論:對接受舒尼替尼治療的轉移性腎癌患者,在舒尼替尼前先應用高劑量IL-2治療可提高療效。

 

 

4. Citation: J Clin Oncol 32:5s, 2014 (suppl; abstr 10028)

 

摘要鏈接:http://abstracts.asco.org/144/AbstView_144_133281.html

 

Immune activation and clinical responses following

long-term infusion of anti-GD2 antibody ch14.18/CHO in

combination with interleukin-2 in high-risk neuroblastoma patients.

 

Abstract:

 

Background: A less toxic treatment using long-term infusion (LTI) of anti-GD2antibody ch14.18/CHO and subcutaneous interleukin-2 (IL-2) may improve outcome in high risk neuroblastoma (NB).

Methods: 53 NB patients received 5/6 cycles of 6×106 IU/m2 s.c. IL-2 (d1-5; 8-12), LTI of 100 mg/m2 ch14.18/CHO (d8-17) and 160 mg/m2 oral 13-cis-RA (d19-32) in a single center program. Usage of i.v.-morphine and scores established for pediatric pain assessment were documented. Effector cells (NK- and T-cell subsets), ch14.18/CHO levels and GD2 specific killing of neuroblastoma cells by ADCC, CDC, and whole blood were analyzed. KIR/KIRL mismatch and Fcγ-receptor polymorphisms were determined with a validated PCR-based method for KIR, HLA, FCGR2A (H131R), -3A (V158F) and -3B (NA1/NA2). Clinical response was assessed following INRG criteria by mIBG, MRI/CT, BM and catecholamines.

Results: LTI of ch14.18/CHO translated into a decreasing degree of i.v. morphine usage allowing for treatment in the outpatient setting. The expansion of effector NK- (3x) and T-cells (2x) was combined with a pro-inflammatory cytokine response (IL-2, IL-6, IL-8, IFNγ). Effective levels of ch14.18/CHO (12.48 ± 0.93 μg/ml) at the end of antibody infusion translated into GD2specific activity against NB cells in functional assays (CDC, ADCC, WBT). Interestingly, ch14.18/CHO levels and functional parameters before subsequent treatment cycles indicate persistent anti-NB activity measurable for the entire treatment period of 6-7 months. Response rates were 41.7 % in mIBG (15/36), 31.8 % MRI/CT (7/22), 28.6 % bone marrow- (6/21) and 38.1 % in catecholamines (8/21). An overall response of 30% (12/40), EFS of 32.4 % (observation 3.2 years, mean: 1.6 years) and an OS of 66.8% (observation 3.9 years, mean: 3.1 years) was observed. Patients with KIR/KIRL mismatch and high affinity FCGR alleles are associated with a longer event-free survival (P = 0.025), which supports NK-cell mediated ADCC as the mechanism of action.

Conclusions: LTI of ch14.18/CHO shows anti-NB activity over the entire treatment period and objective clinical responses.

 

 

長期注射抗GD2抗體ch14.18/CHO聯合IL-2治療高危型成神經細胞瘤

 

治療方案:成神經細胞瘤(NB)患者53例,皮下注射IL-2,5/6周期,第1-5天,第8-12天,600IU/m2;注射ch14.18/CHO,第8-17天,100mg/m2;口服異維A酸,第19-32天。

結果:總緩解率30% (12/40),無病生存率是32.4%(隨訪3.1年,平均1.6),總生存率